ADMA Biologics (NASDAQ:ADMA) Trading 7.6% Higher Following Analyst Upgrade

ADMA Biologics Inc (NASDAQ:ADMA) rose 7.6% during mid-day trading on Wednesday after Raymond James Financial upgraded the stock to a moderate buy rating. Raymond James Financial now has a $21.00 price target on the stock. ADMA Biologics traded as high as $8.77 and last traded at $8.7350. Approximately 314,986 shares were traded during mid-day trading, a decline of 94% from the average daily volume of 5,151,083 shares. The stock had previously closed at $8.12.

Several other analysts also recently commented on ADMA. Wall Street Zen downgraded shares of ADMA Biologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Mizuho dropped their target price on shares of ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Cantor Fitzgerald restated a “neutral” rating on shares of ADMA Biologics in a report on Thursday, March 26th. Canaccord Genuity Group dropped their target price on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Finally, Zacks Research downgraded shares of ADMA Biologics from a “hold” rating to a “strong sell” rating in a report on Tuesday, May 26th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $19.67.

Insider Activity

In other ADMA Biologics news, Director Jerrold B. Grossman acquired 12,500 shares of the stock in a transaction dated Monday, May 11th. The shares were bought at an average cost of $8.01 per share, for a total transaction of $100,125.00. Following the completion of the acquisition, the director directly owned 513,884 shares of the company’s stock, valued at approximately $4,116,210.84. This trade represents a 2.49% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.90% of the stock is owned by company insiders.

Key Headlines Impacting ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: Raymond James upgraded ADMA Biologics to “moderate buy” and set a $21 price target, implying significant upside from recent levels. The Fly / Zacks report
• Neutral Sentiment: Multiple law firms, including Rosen Law Firm, Kirby McInerney, Robbins Geller, Faruqi & Faruqi, and others, announced or reminded investors about a class-action lawsuit and the August 10, 2026 lead-plaintiff deadline. This keeps the legal situation in focus but does not add new business fundamentals.
• Negative Sentiment: The class action alleges ADMA Biologics engaged in channel stuffing, used an undisclosed related-party transaction, and lacked adequate internal controls, which could indicate prior revenue quality concerns and create downside risk if claims gain traction. Holzer & Holzer class action alert
• Negative Sentiment: Several articles frame the stock’s recent weakness as tied to the lawsuit news and claim it followed a sharp prior drop, reinforcing concerns that litigation headlines are the main driver of sentiment right now. BFA Law alert

Institutional Trading of ADMA Biologics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Summit Securities Group LLC acquired a new stake in shares of ADMA Biologics in the fourth quarter valued at approximately $29,000. Rothschild Investment LLC raised its holdings in shares of ADMA Biologics by 373.8% in the third quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,495 shares during the last quarter. Optima Capital LLC acquired a new stake in shares of ADMA Biologics in the fourth quarter valued at approximately $36,000. Clearstead Advisors LLC raised its holdings in shares of ADMA Biologics by 55.7% in the third quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 795 shares during the last quarter. Finally, iSAM Funds UK Ltd acquired a new stake in shares of ADMA Biologics in the third quarter valued at approximately $34,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Stock Down 1.9%

The company has a quick ratio of 3.93, a current ratio of 6.95 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $1.93 billion, a price-to-earnings ratio of 12.24 and a beta of 0.72. The stock’s fifty day moving average price is $9.19 and its 200-day moving average price is $14.20.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.19. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. The company had revenue of $114.49 million for the quarter, compared to the consensus estimate of $139.98 million. During the same period last year, the company earned $0.11 earnings per share. The firm’s revenue was down .3% compared to the same quarter last year. On average, sell-side analysts predict that ADMA Biologics Inc will post 0.84 earnings per share for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.